SG11201911937UA - Amorphous and crystalline forms of ido inhibitors - Google Patents
Amorphous and crystalline forms of ido inhibitorsInfo
- Publication number
- SG11201911937UA SG11201911937UA SG11201911937UA SG11201911937UA SG11201911937UA SG 11201911937U A SG11201911937U A SG 11201911937UA SG 11201911937U A SG11201911937U A SG 11201911937UA SG 11201911937U A SG11201911937U A SG 11201911937UA SG 11201911937U A SG11201911937U A SG 11201911937UA
- Authority
- SG
- Singapore
- Prior art keywords
- amorphous
- crystalline forms
- ido inhibitors
- ido
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527855P | 2017-06-30 | 2017-06-30 | |
| PCT/US2018/040262 WO2019006283A1 (en) | 2017-06-30 | 2018-06-29 | Amorphous and crystalline forms of ido inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201911937UA true SG11201911937UA (en) | 2020-01-30 |
Family
ID=64742242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201911937UA SG11201911937UA (en) | 2017-06-30 | 2018-06-29 | Amorphous and crystalline forms of ido inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11236049B2 (en) |
| EP (1) | EP3644993B1 (en) |
| JP (1) | JP7690284B2 (en) |
| KR (1) | KR102630575B1 (en) |
| CN (1) | CN111093651B (en) |
| AU (1) | AU2018294314B2 (en) |
| BR (1) | BR112019027259A2 (en) |
| CA (1) | CA3066789A1 (en) |
| EA (1) | EA202090119A1 (en) |
| IL (1) | IL271601B2 (en) |
| MX (2) | MX391848B (en) |
| SG (1) | SG11201911937UA (en) |
| WO (1) | WO2019006283A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383313B (en) * | 2017-06-30 | 2025-03-13 | Bristol Myers Squibb Co | Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation |
| CN115278855A (en) * | 2017-11-17 | 2022-11-01 | 瑞典爱立信有限公司 | Signaling TA offsets in NR |
| CN110357813A (en) * | 2018-04-09 | 2019-10-22 | 信达生物制药(苏州)有限公司 | A kind of new indole amine 2,3- dioxygenase inhibitor and its preparation method and application |
| WO2020000236A1 (en) * | 2018-06-27 | 2020-01-02 | 深圳仁泰医药科技有限公司 | Crystal form of (r)-n-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4-yl)cyclohexyl) propionamide |
| EP4027980A1 (en) * | 2019-09-11 | 2022-07-20 | Bristol-Myers Squibb Company | Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors |
| CA3159071A1 (en) * | 2019-11-26 | 2021-06-03 | Tamar I. ROSENBAUM | Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
| AR120935A1 (en) * | 2020-01-02 | 2022-03-30 | Hutchison Medipharma Ltd | AMIDE DERIVATIVES AND USES THEREOF |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
| ME02461B (en) | 2005-05-10 | 2017-02-20 | Incyte Holdings Corp | INDOLEAMINE 2,3-DIOXYGENASE MODULATORS AND METHODS FOR THE USE OF THE SAME |
| KR101607288B1 (en) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | Human monoclonal antibodies to programmed death ligand 1(pd-l1) |
| EP1971583B1 (en) | 2005-12-20 | 2015-03-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (en) | 2006-09-19 | 2008-02-08 | Incyte Corp | COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS. |
| US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| EP2227233B1 (en) | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido inhibitors |
| WO2009156652A1 (en) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Cellular structure containing aluminium titanate |
| AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
| TWI729512B (en) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CN102574924A (en) | 2009-09-03 | 2012-07-11 | 先灵公司 | Anti-gitr antibodies |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| PT2949670T (en) | 2009-12-10 | 2019-05-20 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| NZ705128A (en) | 2010-03-04 | 2015-04-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2011107553A1 (en) | 2010-03-05 | 2011-09-09 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| CN107011438B (en) | 2010-05-04 | 2020-11-20 | 戊瑞治疗有限公司 | Antibodies that bind CSF1R |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
| DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
| KR101981873B1 (en) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | Anti-pd-l1 antibodies and uses thereof |
| RU2658603C2 (en) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Antibodies against human csf-1r and uses thereof |
| CA2861122A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
| AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
| AU2012374617B2 (en) | 2012-05-11 | 2015-09-17 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
| UY34887A (en) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| UY36390A (en) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| UY36391A (en) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO1), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| MX383313B (en) * | 2017-06-30 | 2025-03-13 | Bristol Myers Squibb Co | Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation |
-
2018
- 2018-06-29 IL IL271601A patent/IL271601B2/en unknown
- 2018-06-29 JP JP2020500206A patent/JP7690284B2/en active Active
- 2018-06-29 CN CN201880044036.6A patent/CN111093651B/en active Active
- 2018-06-29 US US16/624,490 patent/US11236049B2/en active Active
- 2018-06-29 CA CA3066789A patent/CA3066789A1/en active Pending
- 2018-06-29 BR BR112019027259-3A patent/BR112019027259A2/en active IP Right Grant
- 2018-06-29 WO PCT/US2018/040262 patent/WO2019006283A1/en not_active Ceased
- 2018-06-29 KR KR1020207002491A patent/KR102630575B1/en active Active
- 2018-06-29 SG SG11201911937UA patent/SG11201911937UA/en unknown
- 2018-06-29 MX MX2019014885A patent/MX391848B/en unknown
- 2018-06-29 AU AU2018294314A patent/AU2018294314B2/en active Active
- 2018-06-29 EP EP18823337.3A patent/EP3644993B1/en active Active
- 2018-06-29 EA EA202090119A patent/EA202090119A1/en unknown
-
2019
- 2019-12-10 MX MX2021015656A patent/MX2021015656A/en unknown
-
2021
- 2021-12-16 US US17/553,434 patent/US12421195B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200115342A1 (en) | 2020-04-16 |
| IL271601B2 (en) | 2024-05-01 |
| BR112019027259A2 (en) | 2020-07-14 |
| AU2018294314B2 (en) | 2024-09-19 |
| JP7690284B2 (en) | 2025-06-10 |
| MX2019014885A (en) | 2020-02-13 |
| CN111093651A (en) | 2020-05-01 |
| WO2019006283A1 (en) | 2019-01-03 |
| US20220169615A1 (en) | 2022-06-02 |
| KR102630575B1 (en) | 2024-01-29 |
| US12421195B2 (en) | 2025-09-23 |
| EP3644993A4 (en) | 2021-03-10 |
| MX391848B (en) | 2025-03-19 |
| AU2018294314A1 (en) | 2020-02-06 |
| IL271601B1 (en) | 2024-01-01 |
| EP3644993A1 (en) | 2020-05-06 |
| US11236049B2 (en) | 2022-02-01 |
| JP2020526520A (en) | 2020-08-31 |
| CN111093651B (en) | 2023-06-06 |
| KR20200020916A (en) | 2020-02-26 |
| IL271601A (en) | 2020-02-27 |
| CA3066789A1 (en) | 2019-01-03 |
| EP3644993B1 (en) | 2023-08-02 |
| MX2021015656A (en) | 2022-02-03 |
| EA202090119A1 (en) | 2020-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271601A (en) | Amorphous and crystalline forms of IDO inhibitors | |
| IL261606A (en) | Substituted inhibitors of menin-mll and methods of use | |
| IL282552A (en) | Crystalline forms of mnk inhibitors | |
| IL267291A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| IL274504A (en) | Acss2 inhibitors and methods of use thereof | |
| IL259801A (en) | Inhibitors of ezh2 and methods of use thereof | |
| HUE062460T2 (en) | Inhibitors of trpc6 | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| ZA201904460B (en) | Inhibitors of nhe-mediated antiport | |
| ZA201906464B (en) | Crystalline forms of (s)-afoxolaner | |
| PL3532457T3 (en) | Crystalline forms of hydroxynorketamine | |
| IL251197A0 (en) | Crystalline forms of tyrosine kinase inhibitors and their salts | |
| PL3529236T4 (en) | Crystalline forms of eravacycline | |
| IL269073A (en) | Crystalline forms of obeticholic acid | |
| PT3327012T (en) | Crystalline forms of bilastine and preparation methods thereof | |
| HUE044559T2 (en) | Scale inhibitor compositions and methods of using | |
| IL270961A (en) | Crystalline form of n-butyldeoxygalactonojirimycin | |
| IL273604A (en) | Novel compounds and their use as selective inhibitors of caspase-2 | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| PT3348546T (en) | Crystalline form of androgen receptor inhibitor and preparation method thereof | |
| IL277866A (en) | Substituted aminothiazoles as inhibitors of nucleases | |
| IL274758A (en) | Crystalline polymorphs of pracinostat and pracinostat salts | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| IL270937A (en) | Crystalline forms of seletalisib | |
| GB201612717D0 (en) | Amorphous and crystaline forms of tadalfil |